In this study, we would like to propose newly identified CD171-highly expressing neoplasms such as alveolar rhabdomyosarcoma and embryonal carcinoma as well as MMR-preserved colorectal adenocarcinomas and p16-negative tonsil squamous cell carcinoma as potential targets for future CD171-targeting therapy. This evidence concerns the gene L1CAM and colorectal adenocarcinoma.